Analyzing Century Therapeutics (NASDAQ:IPSC) and Medivir AB (publ) (OTCMKTS:MVRBF)

Medivir AB (publ) (OTCMKTS:MVRBF) and Century Therapeutics (NASDAQ:IPSC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Medivir AB (publ) and Century Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medivir AB (publ)	0	0	0	0	N/A
Century Therapeutics	0	1	5	0	2.83

Century Therapeutics has a consensus price target of $14.17, suggesting a potential upside of 231.77%. Given Century Therapeutics’ higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Medivir AB (publ).

Institutional and Insider Ownership

23.2% of Medivir AB (publ) shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 7.6% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Medivir AB (publ) and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medivir AB (publ)	N/A	N/A	N/A
Century Therapeutics	-6,115.12%	-54.73%	-31.15%

Valuation & Earnings

This table compares Medivir AB (publ) and Century Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medivir AB (publ)	N/A	N/A	N/A	$32.14	0.03
Century Therapeutics	$2.23 million	121.50	-$136.67 million	($2.29)	-1.83

Medivir AB (publ) has higher earnings, but lower revenue than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Medivir AB (publ), indicating that it is currently the more affordable of the two stocks.

About Medivir AB (publ)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.